Long-term Outcomes After Surgical Resection of Pancreatic Metastases from Renal Clear-Cell Carcinoma.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
31
08
2020
accepted:
15
12
2020
pubmed:
13
2
2021
medline:
18
5
2021
entrez:
12
2
2021
Statut:
ppublish
Résumé
Pancreatic metastases (PM) from renal cell carcinoma (RCC) are uncommon. We herein describe the long-term outcomes associated with pancreatectomy at two academic institutions, with a specific focus on 10-year survival. This investigation was limited to patients undergoing pancreatectomy for PM between 2000 and 2008 at the University of Verona and Memorial Sloan Kettering Cancer Center, allowing a potential for 10 years of surveillance. The probabilities of further RCC recurrence and RCC-related death were estimated using a competing risk analysis (method of Fine and Gray) to account for patients who died of other causes during follow-up. The study population consisted of 69 patients, mostly with isolated metachronous PM (77%). The median interval from nephrectomy to pancreatic metastasectomy was 109 months, whereas the median post-pancreatectomy follow-up was 141 months. The 10-year cumulative incidence of new RCC recurrence was 62.7%. In the adjusted analysis, the relative risk of repeated recurrence was significantly higher in PM synchronous to the primary RCC (sHR = 1.27) and in patients receiving extended pancreatectomy (sHR = 3.05). The 10-year cumulative incidence of disease-specific death was 25.5%. The only variable with an influence on disease-specific death was the recurrence-free interval following metastasectomy (sHR = 0.98). In patients with repeated recurrence, the 10-year cumulative incidence of RCC-related death was 35.4%. In a selected group of patients followed for a median of 141 months and mostly with isolated metachronous PM, resection was associated with a high possibility of long-term disease control in surgically fit patients with metastases confined to the pancreas.
Sections du résumé
BACKGROUND
BACKGROUND
Pancreatic metastases (PM) from renal cell carcinoma (RCC) are uncommon. We herein describe the long-term outcomes associated with pancreatectomy at two academic institutions, with a specific focus on 10-year survival.
METHODS
METHODS
This investigation was limited to patients undergoing pancreatectomy for PM between 2000 and 2008 at the University of Verona and Memorial Sloan Kettering Cancer Center, allowing a potential for 10 years of surveillance. The probabilities of further RCC recurrence and RCC-related death were estimated using a competing risk analysis (method of Fine and Gray) to account for patients who died of other causes during follow-up.
RESULTS
RESULTS
The study population consisted of 69 patients, mostly with isolated metachronous PM (77%). The median interval from nephrectomy to pancreatic metastasectomy was 109 months, whereas the median post-pancreatectomy follow-up was 141 months. The 10-year cumulative incidence of new RCC recurrence was 62.7%. In the adjusted analysis, the relative risk of repeated recurrence was significantly higher in PM synchronous to the primary RCC (sHR = 1.27) and in patients receiving extended pancreatectomy (sHR = 3.05). The 10-year cumulative incidence of disease-specific death was 25.5%. The only variable with an influence on disease-specific death was the recurrence-free interval following metastasectomy (sHR = 0.98). In patients with repeated recurrence, the 10-year cumulative incidence of RCC-related death was 35.4%.
CONCLUSION
CONCLUSIONS
In a selected group of patients followed for a median of 141 months and mostly with isolated metachronous PM, resection was associated with a high possibility of long-term disease control in surgically fit patients with metastases confined to the pancreas.
Identifiants
pubmed: 33575870
doi: 10.1245/s10434-021-09649-w
pii: 10.1245/s10434-021-09649-w
pmc: PMC8119267
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3100-3108Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
Tanis PJ, van der Gaag NA, Busch OR, et al. Systematic review of pancreatic surgery for metastatic renal cell carcinoma. Br J Surg. 2009;96:579–92.
doi: 10.1002/bjs.6606
Zerbi A, Ortolano E, Balzano G, et al. Pancreatic metastasis from renal cell carcinoma: which patients benefit from surgical resection? Ann Surg Oncol. 2008;15:1161–8.
doi: 10.1245/s10434-007-9782-0
Bassi C, Butturini G, Falconi M, et al. High recurrence rate after atypical resection for pancreatic metastases from renal cell carcinoma. Br J Surg. 2003;90:555–9.
doi: 10.1002/bjs.4072
Volk A, Kersting S, Konopke R, et al. Surgical therapy of intrapancreatic metastasis from renal cell carcinoma. Pancreatology. 2009;9:392–7.
doi: 10.1159/000181174
Sweeney AD, Wu MF, Hilsenbeck SG, et al. Value of pancreatic resection for cancer metastatic to the pancreas. J Surg Res. 2009;156:189–98.
doi: 10.1016/j.jss.2009.01.017
Strobel O, Hackert T, Hartwig W, et al. Survival data justifies resection for pancreatic metastases. Ann Surg Oncol. 2009;16:3340–9.
doi: 10.1245/s10434-009-0682-3
Konstantinidis IT, Dursun A, Zheng H, et al. Metastatic tumors in the pancreas in the modern era. J Am Coll Surg. 2010;211:749–53.
doi: 10.1016/j.jamcollsurg.2010.08.017
Masetti M, Zanini N, Martuzzi F, et al. Analysis of prognostic factors in metastatic tumors of the pancreas: a single-center experience and review of the literature. Pancreas. 2010;39:135–43.
doi: 10.1097/MPA.0b013e3181bae9b3
Di Franco G, Gianardi D, Palmeri M, et al. Pancreatic resections for metastases: a twenty-year experience from a tertiary care center. Eur J Surg Oncol. 2020;46:825–31.
doi: 10.1016/j.ejso.2019.11.514
Schwarz L, Sauvanet A, Regenet N, et al. Long-term survival after pancreatic resection for renal cell carcinoma metastasis. Ann Surg Oncol. 2014;21:4007–13.
doi: 10.1245/s10434-014-3821-4
Lee SR, Gemenetzis G, Cooper M, et al. Long-term outcomes of 98 surgically resected metastatic tumors in the pancreas. Ann Surg Oncol. 2017;24:801–7.
doi: 10.1245/s10434-016-5619-z
Adler H, Redmond CE, Heneghan HM, et al. Pancreatectomy for metastatic disease: a systematic review. Eur J Surg Oncol. 2014;40:379–86.
doi: 10.1016/j.ejso.2013.12.022
Huang Q, Zhou H, Liu C, et al. Surgical resection for metastatic tumors in the pancreas: a single-center experience and systematic review. Ann Surg Oncol. 2019;26:1649–56.
doi: 10.1245/s10434-019-07258-2
Jaen-Torrejimeno I, Rojas-Holguín A, López-Guerra D, Ramia JM, Blanco-Fernández G. Pancreatic resection for metastatic renal cell carcinoma. A systematic review. HPB. 2019;S1365-182x:30757–9.
Mihaly Z, Sztupinszki Z, Surowiak P, Gyorffy B. A comprehensive overview of targeted therapy in metastatic renal cell carcinoma. Curr Cancer Drug Targets. 2012;12:857–72.
doi: 10.2174/156800912802429265
Singla N, Xie Z, Zhang Z, et al. Pancreatic tropism of metastatic renal cell carcinoma. JCI Insight. 2020;5:134564.
doi: 10.1172/jci.insight.134564
Santoni M, Conti A, Partelli S, et al. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. Ann Surg Oncol. 2015;22:2094–100.
doi: 10.1245/s10434-014-4256-7
Malleo G, Vollmer CM Jr. Postpancreatectomy complications and management. Surg Clin North Am. 2016;96:1313–36.
doi: 10.1016/j.suc.2016.07.013
Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerback AD. A note on competing risk in survival data analysis. Br J Cancer. 2004;91:1229–35.
doi: 10.1038/sj.bjc.6602102
Schuster NA, Hoogendijk EO, Kok AAL, Twisk JWR, Heymans MW. Ignoring competing events in the analysis of survival data may lead to biased results: a nonmathematical illustration of competing risk analysis. J Clin Epidemiol. 2020;122:42–8.
doi: 10.1016/j.jclinepi.2020.03.004
Noguchi G, Nakaigawa N, Taguri M, et al. Time-dependent change in relapse sites of renal cell carcinoma after curative surgery. Clin Exp Metastasis. 2018;35:69–75.
doi: 10.1007/s10585-018-9883-0
Antonelli A, Furlan M, Sodano M, et al. Features, risk factors and clinical outcome of “very late” recurrences after surgery for localized renal carcinoma: a retrospective evaluation of a cohort with a minimum of 10 years of follow up. Int J Urol. 2016;23:36–40.
doi: 10.1111/iju.12962
Miyao N, Naito S, Ozono S, et al. Late recurrence of renal cell carcinoma: retrospective and collaborative study of the Japanese Society of Renal Cancer. Urology. 2011;77:379–84.
doi: 10.1016/j.urology.2010.07.462
Grassi P, Doucet L, Giglione P, et al. Clinical impact of pancreatic metastases from renal cell carcinoma: a multicenter retrospective analysis. PLoS One. 2016;11:e0151662.
doi: 10.1371/journal.pone.0151662
Ljungberg B, Albiges L, Bensalah A, et al. European Association of Urology (EAU) guidelines on renal cell carcinoma, 2019. Available at http://uroweb.org/guideline/renal-cell-carcinoma/ .
Santini D, Santoni M, Conti A, et al. Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. Oncotarget. 2016;7:33381–90.
doi: 10.18632/oncotarget.8302
Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454–63.
doi: 10.1200/JCO.2004.06.132
Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23:832–41.
doi: 10.1200/JCO.2005.05.179